© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
November 21, 2022
"The idea that we may have reliable and consistently interpretable tests for these patients is exciting for the future," says Benjamin Lowentritt, MD, FACS.
November 17, 2022
“As the PSMA-PET market for access has grown, the coverage has actually been better than we anticipated when it first launched,” says David Morris, MD.
November 16, 2022
“PSMA scanning is definitely a game-changer with regard to imaging in advanced prostate cancer in urology,” says Evan R. Goldfischer, MD.
November 14, 2022
177Lu-PSMA-617 is approved by the FDA for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting.
November 08, 2022
The co-primary end points have been achieved in the phase 3 ZIRCON trial exploring the novel PET imaging radiopharmaceutical TLX250-CDx in clear cell renal cell carcinoma.
November 04, 2022
64Cu SAR-Bombesin targets the Gastrin Releasing Peptide receptor, which is found on prostate tumors as well as several other tumors.
October 28, 2022
"During treatment with 177Lu-PSMA-617, patients should be counseled to increase oral fluid intake and to void frequently to reduce bladder radiation exposure," writes Stephanie Trexler, PharmD, BCOP.
October 26, 2022
New findings from the phase 3 SPOTLIGHT trial show the impact of PSA level, PSA doubling time, Gleason score, and prior therapy on 18F-rhPSMA-7.3 detection rates.
October 20, 2022
A recent study suggests that radiomics analysis based on 68Ga-PSMA-11 PET may non-invasively predict intraprostatic lesions in patients with prostate cancer.
October 18, 2022
Illuccix is indicated for use in patients with suspected metastasis who are candidates for initial definitive therapy, or in patients with suspected recurrence based on elevated PSA level.